CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

Nodular sclerosing Hodgkin lymphoma

Human disease

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionFeb 11, 2026
Entity authorityQ17126784 ↗
Source-derived summary

Nodular sclerosing Hodgkin lymphoma ("NSHL") or Nodular sclerosis is a form of Hodgkin lymphoma that is the most common subtype of HL in developed countries. It affects females slightly more than males and has a median age of onset at ~28 years. It is composed of large tumor nodules with lacunar Reed–Sternberg cell (RS cells) surrounded by fibrotic collagen bands.

The British National Lymphoma Investigation further categorized NSHL based upon Reed–Sternberg cells into "nodular sclerosis type I" (NS I) and "nodular sclerosis type II" (NS II), with the first subtype responding better to treatment.

Editorial summary

“Nodular sclerosing Hodgkin lymphoma” enters the record as human disease. Crown Archives preserves that source wording while asking what Nodular, sclerosing and Hodgkin can confirm, complicate or overturn.

Editorial reviewA concise reference frame for defining the subject, testing terminology and identifying the institution closest to the evidence. The current 94-word lead offers orientation but no explicit four-digit date, so chronology should not be assumed. The selected authority fields contribute no independent date. Its strongest next move is a source search built around Nodular, sclerosing and Hodgkin.
Editorial analysis

Why this record matters

“Nodular sclerosing Hodgkin lymphoma” is worth following because a concise public description often conceals a longer documentary argument. Here, Nodular, sclerosing and Hodgkin provides the most credible route into that argument.

Evidence profile

Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Feb 11, 2026. The linked authority identifier is Q17126784. None of the 0 selected statements returned an explicit reference.

Critical limits

Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “Nodular sclerosing Hodgkin lymphoma”, its source revision and the description used here.
  2. Expand the search: follow Nodular sclerosing Hodgkin lymphoma primary sources, Nodular sclerosing Hodgkin lymphoma archive and Nodular research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Nodular sclerosing Hodgkin lymphoma”?
  2. Which institution is responsible for the underlying evidence?
  3. What terminology or title could unlock a more precise catalogue search?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Nodular sclerosing Hodgkin lymphoma” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.